TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.52 USD
-0.02 (-1.30%)
Updated Nov 7, 2024 03:41 PM ET
After-Market: $1.55 +0.03 (1.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.52 USD
-0.02 (-1.30%)
Updated Nov 7, 2024 03:41 PM ET
After-Market: $1.55 +0.03 (1.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will TherapeuticsMD (TXMD) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: TherapeuticsMD (TXMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in TherapeuticsMD (TXMD) Stock?
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 31.58% and 200.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -5.56% and 19.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: TherapeuticsMD (TXMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD Enters Agreement to Market Drugs Outside US
by Zacks Equity Research
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.88% and -41.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
Earnings Preview: TherapeuticsMD (TXMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock
by Zacks Equity Research
Investors in TherapeuticsMD (TXMD) need to pay close attention to the stock based on moves in the options market lately.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.